#USA #New York #Pomerantz LLP #SLNO #Solen Therapeutics

Pomerantz Law Firm Investigates Possible Misconduct at Soleno Therapeutics

As concerns mount over corporate integrity, Pomerantz LLP has taken a proactive stance, launching an investigation on behalf of investors in Soleno Therapeutics, Inc. (NASDAQ: SLNO). The law firm, which is well-regarded for handling class-action lawsuits in corporate, securities, and antitrust law, is delving into allegations of potential securities fraud involving the company and certain officers or directors. This investigation was triggered by a critical report released by Scorpion Capital, which labeled Soleno’s sole product, Vykat XR, as both overpriced and possibly hazardous for children.

The implications of Scorpion's report were immediately reflected in the stock market. Following the announcement, Soleno's stock price plummeted by $5.73 per share, constituting a staggering 7.41% drop and closing at $71.63 per share on August 15, 2025. Such a dramatic decline raises red flags for investors, leading many to seek legal recourse to reclaim potential losses.

Pomerantz LLP, with its extensive experience spanning over 85 years, prides itself on advocating for victims of securities fraud and breaches of fiduciary duty. The firm's history dates back to its founder, Abraham L. Pomerantz, who is recognized as a pioneer in the field of securities class actions. His legacy endures as Pomerantz continues to represent investors and fight against corporate malpractice, aiming to secure fair damages for those affected.

Investors who had shares in Soleno during the reported time frame are encouraged to contact Pomerantz to explore their legal options. Danielle Peyton can be reached at [email protected] or by phone at 646-581-9980, ext. 7980. Joining a class action can be a vital step for those looking to hold the company accountable for its alleged missteps.

It’s crucial for investors to stay informed about the changing circumstances surrounding Soleno Therapeutics as the investigation unfolds. Transparency and accountability in corporate governance are fundamental principles that protect the interests of shareholders and uphold investor confidence in the market.

As the situation develops, Pomerantz's findings may lead to significant legal ramifications for the company and its executives if any fraudulent activities are confirmed. Investors should remain vigilant and consider their rights in the context of potential class action suits, as the legal landscape can heavily influence the prospects of recuperating lost investments.

In the realm of pharmaceuticals, where the stakes are considerably high, scrutiny from law firms and watchdog organizations is essential to ensuring that companies maintain ethical practices. Keeping a close watch on these developments is imperative for anyone invested in or considering investment in Soleno Therapeutics.

For further updates, follow Pomerantz LLP's communications, as they continue to navigate the complexities of this case and advocate for affected investors. Investors should always ensure that their interests are protected through diligent monitoring of company activities and engaging with trusted legal professionals whenever necessary.